Drugs / ASG-5ME
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01228760 | Oct 2010 → Feb 2013 | prostate neoplasm | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT01166490 | Jul 2010 → Jul 2013 | gastric neoplasm, pancreatic neoplasm | Seagen Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASG-5ME | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01166490 ↗ |
| Route | Intravenous | “0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles” NCT01166490 ↗ |
| Target | SLC44A4 | “Choline transporter-like protein 4 binding agent” CHEMBL2109574 ↗ |